Licensing Terms and Agreements in Pharma, Biotech and Diagnostics is a new market research publication announced by Reportstack. This report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter licensing deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of licensing dealmaking and business activities.This report provides-an analysis of the trends in licensing as well as a discussion on the merits of the type of deal, an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part, a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database, a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials, a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand, a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.
Companies Mentioned
Johnson&Johnson
Novartis Roche Pfizer Sanofi Merck and Co GlaxoSmithKline Bayer Fresenius AstraZeneca Eli Lilly Abbott Boehringer Ingelheim Teva Abbvie Amgen Takeda Bristol-Myers Squibb Novo Nordisk Baxter Merck KGaA Otsuka Astellas Daiichi Sankyo Gilead Sciences Actavis Biogen Idec Mylan Celgene Allergan Eisai Servier Valeant Pharmaceuticals CSL Shire UCB
Chugai Mitsubishi Tanabe Hospira Dainippon Sumitomo Forest Menarini Kyowa Hakko Kirin Grifols Shionogi Lundbeck Aspen Pharmacare Endo Pharmaceuticals Sun Pharmaceuticals Purdue
The report provides a detailed understand and analysis of how and why companies enter licensing deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of licensing dealmaking and business activities.This report provides-an analysis of the trends in licensing as well as a discussion on the merits of the type of deal, an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part, a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database, a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials, a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand, a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.
Companies Mentioned
Johnson&Johnson
Novartis Roche Pfizer Sanofi Merck and Co GlaxoSmithKline Bayer Fresenius AstraZeneca Eli Lilly Abbott Boehringer Ingelheim Teva Abbvie Amgen Takeda Bristol-Myers Squibb Novo Nordisk Baxter Merck KGaA Otsuka Astellas Daiichi Sankyo Gilead Sciences Actavis Biogen Idec Mylan Celgene Allergan Eisai Servier Valeant Pharmaceuticals CSL Shire UCB
Chugai Mitsubishi Tanabe Hospira Dainippon Sumitomo Forest Menarini Kyowa Hakko Kirin Grifols Shionogi Lundbeck Aspen Pharmacare Endo Pharmaceuticals Sun Pharmaceuticals Purdue
To view the table of contents and know more details please visit Licensing Terms and Agreements in Pharma, Biotech and Diagnostics.
No comments:
Post a Comment